CORLINE
Corline Heparin Technology - Enabling Regenerative Medicine
| Coordinatore | NORDICBLUE AB
Organization address
address: Kristinedalsvaegen 48 contact info |
| Nazionalità Coordinatore | Sweden [SE] |
| Totale costo | 1˙465˙000 € |
| EC contributo | 1˙135˙500 € |
| Programma | FP7-SME
Specific Programme "Capacities": Research for the benefit of SMEs |
| Code Call | FP7-SME-2010-1 |
| Funding Scheme | BSG-SME |
| Anno di inizio | 2011 |
| Periodo (anno-mese-giorno) | 2011-04-01 - 2013-09-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
NORDICBLUE AB
Organization address
address: Kristinedalsvaegen 48 contact info |
SE (NACKA) | coordinator | 84˙000.00 |
| 2 |
CORLINE SYSTEMS AB
Organization address
address: LEFFLERSGATAN 5 contact info |
SE (UPPSALA) | participant | 538˙500.00 |
| 3 |
BETA-CELL
Organization address
address: RESEARCHPARK Z.1. 310 contact info |
BE (ZELLIK) | participant | 250˙500.00 |
| 4 |
Tissue Regenix Limited
Organization address
address: INNOVATION WAY THE BIOCENTRE contact info |
UK (York) | participant | 231˙000.00 |
| 5 |
Cytonet GmbH & Co. KG
Organization address
address: Albert-Ludwig-Grimm-Str. 20 contact info |
DE (Weinheim) | participant | 13˙500.00 |
| 6 |
Aurigon Life Science GmbH
Organization address
address: Bahnhofstrasse 9 - 15 contact info |
DE (Tutzing) | participant | 3˙000.00 |
| 7 |
MEDIZINISCHE HOCHSCHULE HANNOVER
Organization address
address: Carl-Neuberg-Strasse 1 contact info |
DE (HANNOVER) | participant | 3˙000.00 |
| 8 |
Stricent AB
Organization address
address: St Lars vag 42 contact info |
SE (Lund) | participant | 3˙000.00 |
| 9 |
UNIVERSITY OF LEEDS
Organization address
address: WOODHOUSE LANE contact info |
UK (LEEDS) | participant | 3˙000.00 |
| 10 |
UPPSALA LANS LANDSTING
Organization address
address: SLOTTSGRAND 2A contact info |
SE (UPPSALA) | participant | 3˙000.00 |
| 11 |
VRIJE UNIVERSITEIT BRUSSEL
Organization address
address: PLEINLAAN 2 contact info |
BE (BRUSSEL) | participant | 3˙000.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Regenerative Medicine (use of cells and tissue to replace or heal impaired functions in the body, RM) is one of the fastest growing areas in today’s medicine, and has the potential to offer treatment to patients with diseases that are currently untreatable. In many new areas of RM there is however a need to improve the outcome of RM concepts and technologies for it to become a viable option to traditional medicine, or even to motivate the risk of clinical trials and treatments. One of the main problems in several RM areas is that a large portion of the cell and tissue material is lost or made dysfunctional during and shortly after transplantation and that the transplant does not connect to the host tissue as a functional new graft. The specific scientific objective of this project is twofold: 1) to clinically test and prove that Corline Heparin Surfaces (CHS) can be used to protect donated human insulin producing cells that are transplanted to severe cases of Diabetes Type 1 patients, and 2) to broaden the application of the technology and show that the CHS technology can function as a protective and revascularization promoting technology for other Regenerative Medicine areas. The goal is to show CHS’s further applicability to Liver Cell therapy, Xeno transplantation of Islet of Langerhans and to Tissue Engineering In addition to the detailed scientific objective, this project has a specific technological objective. The technological objective of this project is to, in partnerships with the participating SMEs, improve European top grade clinical Regenerative Medicine products by combining them with the CHS technology, transferring the application knowledge and integrating the CHS technology into the partners’ cell and tissue production processes, and to set up a reliable sourcing chain with supply and production of reagents and tissue products to end-user.'
Introduzione (Teaser)
EU research has funded a remarkable breakthrough in regenerative medicine. Protection and encapsulation for cells in a tissue graft are poised to enter clinical practise.